EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte Studie

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity

Sean Wharton, Ildiko Lingvay iD, Pawel Bogdanski, Ruben Duque do Vale, Stephan Jacob, Tobias Karlsson, Chaithra Shaji, Domenica Rubino, W Timothy Garvey, OASIS 4 Study Group

New England Journal of Medicine · 18.09.2025 · 393 (11) · 1077-1087

DOI: 10.1056/nejmoa2500969 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 18.09.2025. Verfasst von Sean Wharton und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Toronto, Toronto. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity, Overweight, Weight Loss. Die Arbeit wurde bisher 154-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsObesityOverweightWeight LossGlucagon-Like Peptide-1 Receptor AgonistsAdultAgedFemaleHumansMaleMiddle AgedAdministration, OralBody Mass IndexDouble-Blind MethodLife StyleQuality of LifeDose-Response Relationship, DrugGlucagon-Like Peptide 1Treatment OutcomeSemaglutide

Substanzen

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • University of Toronto, Toronto.
  • York University, Toronto.
  • McMaster University, Hamilton, ON, Canada.
  • Wharton Weight Management Clinic, Burlington, ON, Canada.
  • Department of Internal Medicine and Endocrinology, University of Texas Southwestern Medical Center, Dallas.
  • Peter O' Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas.

ORCID-Profile: Ildiko Lingvay

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Wharton, S., Lingvay, I., Bogdanski, P., Duque do Vale, R., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., Garvey, W. T., & OASIS 4 Study Group (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine, 393(11), 1077-1087. https://doi.org/10.1056/nejmoa2500969

Vancouver

Wharton S, Lingvay I, Bogdanski P, Duque do Vale R, Jacob S, Karlsson T, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine. 2025;393(11):1077-1087. doi:10.1056/nejmoa2500969

BibTeX
@article{Wharton2025,
  author = {Wharton, Sean and Lingvay, Ildiko and Bogdanski, Pawel and Duque do Vale, Ruben and Jacob, Stephan and Karlsson, Tobias and Shaji, Chaithra and Rubino, Domenica and Garvey, W Timothy and OASIS 4 Study Group, OASIS 4 Study Group},
  title = {Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {11},
  pages = {1077--1087},
  doi = {10.1056/nejmoa2500969}
}
Kostenlos starten →